PET-Specific Parameters and Radiotracers in Theoretical Tumour Modelling
暂无分享,去创建一个
[1] A. Scott,et al. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. , 2007, Seminars in nuclear medicine.
[2] Jin Mo Goo,et al. False Positive and False Negative FDG-PET Scans in Various Thoracic Diseases , 2006, Korean journal of radiology.
[3] Cyrill Burger,et al. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] Daniela Thorwarth,et al. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia , 2005, Physics in medicine and biology.
[5] Badreddine Bencherif,et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] P. Tracqui,et al. Biophysical models of tumour growth , 2009 .
[7] Vittorio Cristini,et al. Multiscale cancer modeling. , 2010, Annual review of biomedical engineering.
[8] P. Maini,et al. The role of acidity in solid tumour growth and invasion. , 2005, Journal of theoretical biology.
[9] Robert Jeraj,et al. Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data , 2012, Physics in medicine and biology.
[10] T W Griffin,et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.
[11] Mark A Mintun,et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.
[12] E Bezak,et al. Efficient Monte Carlo modelling of individual tumour cell propagation for hypoxic head and neck cancer , 2008, Physics in medicine and biology.
[13] Keigo Endo,et al. Additional value of integrated PET/CT over PET alone in the initial staging and follow up of head and neck malignancy , 2010, Annals of nuclear medicine.
[14] John L. Humm,et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging , 2008, Physics in medicine and biology.
[15] A. Scarsbrook,et al. False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging. , 2011, Clinical radiology.
[16] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[17] Heiko Schöder,et al. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. , 2009, Seminars in nuclear medicine.
[18] David A. Mankoff,et al. Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol , 2008, Journal of Nuclear Medicine.
[19] Robert Jeraj,et al. An imaging-based stochastic model for simulation of tumour vasculature , 2012, Physics in medicine and biology.
[20] R. Coleman,et al. Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.
[21] Roland Bares,et al. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[22] H. Frieboes,et al. Predictive oncology: A review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth , 2007, NeuroImage.
[23] G. V. von Schulthess,et al. Why most PET of lung and head-and-neck cancer will be PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] W. De Wever,et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT , 2006, European Radiology.
[25] Marvin Bergsneider,et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] H. Frieboes,et al. Nonlinear modelling of cancer: bridging the gap between cells and tumours , 2010, Nonlinearity.
[27] F Dehdashti,et al. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[28] Horst Kessler,et al. Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.
[29] Wei Chen,et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Buck,et al. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[31] Tinsu Pan,et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. , 2006, AJR. American journal of roentgenology.
[32] Jean-Claude Liehn,et al. Positron Emission Tomography in oncology: present and future of PET and PET/CT. , 2009, Critical reviews in oncology/hematology.
[33] M J Welch,et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] M. Dewhirst,et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.
[35] Alfred A Bartolucci,et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. , 2004, The Annals of thoracic surgery.
[36] Y Yonekura,et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] Paul Kinahan,et al. A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] Stephan K. Haerle,et al. Contrast‐enhanced 18F‐FDG‐PET/CT for the assessment of necrotic lymph node metastases , 2010, Head & neck.
[39] Stefano Fanti,et al. 18F-DOPA PET and PET/CT , 2007, Journal of Nuclear Medicine.
[40] Robert Jeraj,et al. Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response , 2013, The Journal of Nuclear Medicine.
[41] Kieran Smallbone,et al. Mathematical modelling of tumour acidity. , 2008, Journal of theoretical biology.
[42] C. Meltzer,et al. PET/CT: form and function. , 2007, Radiology.
[43] Robert Jeraj,et al. An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response , 2008, Physics in medicine and biology.
[44] Tomio Inoue,et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study , 2011, Annals of nuclear medicine.
[45] Federico Turkheimer,et al. Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future , 2012, Molecular Imaging and Biology.
[46] Christophe Van de Wiele,et al. Molecular imaging of hypoxia with radiolabelled agents , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[47] William M. Wells,et al. Medical Image Computing and Computer-Assisted Intervention — MICCAI’98 , 1998, Lecture Notes in Computer Science.
[48] E. T. Gawlinski,et al. A reaction-diffusion model of cancer invasion. , 1996, Cancer research.
[49] Ora Israel,et al. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[50] Michael Brady,et al. A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data , 2006, Physics in medicine and biology.
[51] Leyun Pan,et al. Shortened Acquisition Protocols for the Quantitative Assessment of the 2-Tissue-Compartment Model Using Dynamic PET/CT 18F-FDG Studies , 2011, The Journal of Nuclear Medicine.
[52] Ronald M. Summers,et al. Patient specific tumor growth prediction using multimodal images , 2014, Medical Image Anal..
[53] Ronald M. Summers,et al. Multimodal Image Driven Patient Specific Tumor Growth Modeling , 2013, MICCAI.
[54] E. T. Gawlinski,et al. Acid-mediated tumor invasion: a multidisciplinary study. , 2006, Cancer research.
[55] Qimin He,et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.
[56] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[57] A. Shields,et al. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] L. Wiens,et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] M. Spieth,et al. A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[60] Yana K. Reshetnyak,et al. Towards the improvement of an acidosis-targeting peptide PET tracer , 2012 .
[61] Dan Grandér,et al. How do mutated oncogenes and tumor suppressor genes cause cancer? , 1998, Medical oncology.
[62] Michael A. Blake,et al. Oral and IV contrast agents for the CT portion of PET/CT. , 2010, AJR. American journal of roentgenology.
[63] Georgios Karanikas,et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[64] Tomio Inoue,et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[65] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] Yuichi Kimura,et al. PET kinetic analysis—compartmental model , 2006, Annals of nuclear medicine.
[67] Yana K Reshetnyak,et al. A novel technology for the imaging of acidic prostate tumors by positron emission tomography. , 2009, Cancer research.
[68] Ludwig G Strauss,et al. Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[69] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[70] John R. King,et al. Vanishing beyond all orders: Stokes lines in a water-wave model equation , 2009 .
[71] Christine Leininger,et al. Van de Wiele , 2005 .
[72] Thomas Beyer,et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.
[73] Robert J. Gillies,et al. Tumor pH and Its Measurement , 2010, The Journal of Nuclear Medicine.